YLHM
TEVA icon

Yelin Lapidot Holdings Management’s Teva Pharmaceuticals TEVA Stock Holding History

Yelin Lapidot Holdings Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9M Sell
352,579
-2,125
-0.6% -$70.8K 2.26% 12
2026
Q1 		$10.7M Sell
354,704
-40,800
-10% -$1.31M 2.23% 13
2025
Q4 		$12.3M Hold
395,504
– – 2.47% 11
2025
Q3 		$7.99M Hold
395,504
– – 1.68% 16
2025
Q2 		$6.63M Hold
395,504
– – 1.21% 23
2025
Q1 		$6.08M Hold
395,504
– – 1.17% 23
2024
Q4 		$8.72M Sell
395,504
-126,440
-24% -$2.3M 1.52% 18
2024
Q3 		$9.41M Sell
521,944
-18,260
-3% -$320K 1.55% 19
2024
Q2 		$8.78M Hold
540,204
– – 1.55% 18
2024
Q1 		$7.62M Hold
540,204
– – 1.57% 20
2023
Q4 		$5.64M Hold
540,204
– – 1.36% 19
2023
Q3 		$5.52M Buy
+540,204
New +$5.03M 1.36% 21

Other funds holding TEVA

HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return

Yelin Lapidot Holdings Management's TEVA Position: Q2 2026 in Review

Yelin Lapidot Holdings Management reduced its Teva Pharmaceuticals (TEVA) stake by 0.6% in Q2 2026, selling an estimated $70.8K and leaving 352,579 shares worth $11.9M. The position accounts for 2.26% of the portfolio, ranked #12.

Yelin Lapidot Holdings Management first reported a position in TEVA in Q3 2023 and has held it in 12 quarters since. The position peaked at $12.3M in Q4 2025. 246 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Yelin Lapidot Holdings Management held 352,579 shares of Teva Pharmaceuticals worth $11.9M as of Q2 2026.
  • Yelin Lapidot Holdings Management sold 2,125 Teva Pharmaceuticals shares in Q2 2026, an estimated $70.8K.
  • Teva Pharmaceuticals made up 2.26% of Yelin Lapidot Holdings Management's portfolio in Q2 2026, its #12 holding.
  • Yelin Lapidot Holdings Management first reported a position in Teva Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Yelin Lapidot Holdings Management's Teva Pharmaceuticals position peaked at $12.3M in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Yelin Lapidot Holdings Management's 13F filing for Q2 2026, filed 3 Aug 2026.